Preliminary Data From a Phase 1/2 Trial of PDS01ADC Plus Docetaxel in mCRPC

/in , , , /by

Preliminary results from an ongoing phase 1/2 trial combining docetaxel with the tumor-targeting IL-12 immunocytokine PDS01ADC  (aka M9241) indicate promising early activity in patients with metastatic castration-resistant prostate cancer (mCRPC). The single-arm study, presented at the American Association for Cancer Research special conference on prostate cancer research, enrolled 16 patients with progressive mCRPC, most of […]

Read more

ARREST Trial: Precision Radiation Boosts to Fix 177Lu-PSMA’s 50% Failure Rate

/in , , /by

ARREST trial could change mCRPC treatment by solving 177Lu-PSMA’s biggest limitation: up to 50% of patients get little benefit despite FDA approval and proven survival gains. The simple idea? Add targeted external beam radiation boosts to the tumors that radioligand therapy misses, creating a hybrid approach that could cut skeletal complications dramatically. Current 177Lu-PSMA therapy […]

Read more

SL-28 Phase 1/2 Trial: A Potential Breakthrough for Advanced Solid Tumors

/in , , , /by

SL-28 is a new type of donor cell therapy called Leukocyte-Tells. These cells come from healthy donors and get prepared outside the body to better fight cancer. They make more cancer-killing compounds, eat tumor cells, release enzymes, produce helpful signals, and move well toward tumors. Unlike other cell therapies, SL-28 does not need to match […]

Read more

UPDATE: SECuRE Trial Phase 2 Shows 67% PSA50 Response in Heavily Pre-Treated mCRPC

/in , , /by

The latest interim update from the SECuRE trial reinforces the impression that copper‑67 PSMA targeting is emerging as a credible contender in the mCRPC radioligand space, with consistent PSA responses and a clean safety profile in a small but challenging population. The Safety Review Committee has endorsed continuation of the Phase 2 cohort expansion without […]

Read more

Phase 1 Trial: STEAP1 CAR‑T Plus Enzalutamide A New Immune Approach for mCRPC

/in , , , /by

STEAP1 is a protein that sits on the surface of many prostate cancer cells, especially in advanced metastatic disease. Because it is abundant on cancer cells and much less present in normal tissues, STEAP1 looks like a promising “flag” that engineered immune cells can use to distinguish tumor from healthy organs. ​ The treatment being […]

Read more

ANDROMEDA: Phase 1/2 Trial of AZD9750 AR Degrader in Metastatic Prostate Cancer

/in , , , /by

The ANDROMEDA trial, a first-in-human Phase 1/2 study, is evaluating AZD9750, a novel androgen receptor (AR) PROTAC, in men with metastatic castration-resistant prostate cancer (mCRPC). PROTACs represent a paradigm shift in targeted therapy: unlike traditional AR inhibitors that merely block the receptor’s activity, AZD9750 recruits cellular machinery to completely degrade the AR protein, potentially overcoming […]

Read more

GSK5471713: An Investigational AR Degrader Targeting Late-Stage Prostate Cancer Resistance

/in , , , /by

Note: This article treats GSK5471713 as an androgen receptor (AR) degrader based on GSK’s official clinical trial registry classification and inclusion/exclusion criteria. While confident in the AR degrader designation from the sponsor’s documentation, the specific degradation mechanism (PROTAC, SARD, or other platform) remains undisclosed in publicly available sources at the moment. GSK5471713 is an investigational […]

Read more

BrUOG360 Phase Ib/II Trial: Copanlisib Plus Rucaparib for mCRPC With HRD

/in , , , /by

Copanlisib combined with rucaparib demonstrates tolerability and early signals of activity in metastatic castration-resistant prostate cancer (mCRPC), according to results from the BrUOG360 phase Ib/II trial published in late 2025. ​Metastatic castration-resistant prostate cancer with homologous recombination deficiency (HRD) responds to PARP inhibitors like rucaparib, but many patients develop resistance through alternative DNA repair pathways. […]

Read more

Dapagliflozin and Next-Generation Hormonal Agents: Targeting Metabolic Resistance in Metastatic Castrate-Resistant Prostate Cancer

/in , , /by

A new phase 2 clinical trial is now underway to test whether adding dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, to next-generation hormonal agents (darolutamide, abiraterone, apalutamide, enzalutamide) can extend survival in metastatic castrate-resistant prostate cancer. The rationale rests on a fundamental paradox in prostate cancer biology: while early tumors rely on oxidative metabolism and androgen signaling, […]

Read more

GVV858: A New Approach to Castration-Resistant Prostate Cancer Phase 1/2 Trial

/in , , , /by

GVV858 is a CDK2 inhibitor designed to block this escape route. Instead of adding another hormone therapy when resistance develops, it targets the cell cycle machinery that CCNE1-amplified tumors depend on. The drug works on the molecular brakes that control when cells divide, rather than trying to manipulate hormone levels further. CCNE1 amplification allows cancer […]

Read more